Gene targeting techniques for Huntington's disease

被引：18

作者：

Fields, Eric ^{[1
]}

Vaughan, Erik ^{[1
]}

Tripu, Deepika ^{[1
]}

Lim, Isabelle ^{[1
]}

Shrout, Katherine ^{[1
]}

Conway, Jessica ^{[1
]}

Salib, Nicole ^{[1
]}

Lee, Yubin ^{[1
]}

Dhamsania, Akash ^{[1
]}

Jacobsen, Michael ^{[1
]}

Woo, Ashley ^{[1
]}

Xue, Huijing ^{[2
]}

Cao, Kan ^{[1
,2
]}

机构：

[1] Univ Maryland, Gemstone Honors Program, College Pk, MD 20742 USA

[2] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA

来源：

AGEING RESEARCH REVIEWS | 2021年 / 70卷

关键词：

Huntington's disease; Allele-specific targeting; Prime editing; SNPs; MUTANT HUNTINGTIN; CAG REPEAT; GUT MICROBIOTA; MOUSE MODEL; RNA; MECHANISMS; THERAPY; PHOSPHORYLATION; INACTIVATION; CILIOGENESIS;

D O I：

10.1016/j.arr.2021.101385

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by extended trinucleotide CAG repetition in the HTT gene. Wild-type huntingtin protein (HTT) is essential, involved in a variety of crucial cellular functions such as vesicle transportation, cell division, transcription regulation, autophagy, and tissue maintenance. The mutant HTT (mHTT) proteins in the body interfere with HTT's normal cellular functions and cause additional detrimental effects. In this review, we discuss multiple approaches targeting DNA and RNA to reduce mHTT expression. These approaches are categorized into non-allele-specific silencing and allele-specificsilencing using Single Nucleotide Polymorphisms (SNPs) and haplogroup analysis. Additionally, this review discusses a potential application of recent CRISPR prime editing technology in targeting HD.

引用

页数：8

共 50 条

[21] The potential of gene editing for Huntington's disease
Duan, Wenzhen
Urani, Ece
Mattson, Mark P.
TRENDS IN NEUROSCIENCES, 2023, 46 (05) : 365 - 376
[22] PSYCHOSIS IN HUNTINGTON'S DISEASE CARRIER GENE
Garg, Vikas
Rajapakse, Shammi
Macgregor, Robyn
Jardim, Manuel
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2013, 47 (S1): : 47 - 47
[23] Cell and gene therapy for Huntington's disease
Song, Jihwan
TISSUE ENGINEERING PART A, 2022, 28 : 346 - 346
[24] Characterising the Huntington's disease gene product
Wood, J
Macmillan, JC
Thomas, P
Lowenstein, PR
Harper, PS
Jones, AL
BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (04) : S595 - S595
[25] Huntington's Disease Muting the responsible Gene
不详
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2016, 84 (05) : 256 - 256
[26] Therapeutic gene silencing in Huntington's disease
Aronin, Neil
JOURNAL OF MEDICAL GENETICS, 2007, 44 : S22 - S22
[27] Gene therapy approach for Huntington's disease
Betuing, Sandrine
Piguet, Francoise
Mailly, Philippe
Hu, Amelie
Cartier, Nathalie
Aubourg, Patrick
Caboche, Jocelyne
HUMAN GENE THERAPY, 2011, 22 (06) : A21 - A21
[28] Neuroimaging Techniques in Huntington's Disease: A Critical Review
Farag, Mena
Knights, Harry
Scahill, Rachael I.
Mccolgan, Peter
Estevez-Fraga, Carlos
MOVEMENT DISORDERS CLINICAL PRACTICE, 2025,
[29] Efficient repetitive alteration of the mouse Huntington's disease gene by management of background in the tag and exchange gene targeting strategy
Cearley, JA
Detloff, PJ
TRANSGENIC RESEARCH, 2001, 10 (06) : 479 - 488
[30] Efficient repetitive alteration of the mouse Huntington's disease gene by management of background in the tag and exchange gene targeting strategy
Jamie A. Cearley
Peter J. Detloff
Transgenic Research, 2001, 10 : 479 - 488

← 1 2 3 4 5 →